Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations

Summary

This is an open-label, nonrandomized phase 2 trial to assess the efficacy of cobimetinib in RAS pathway activated CMML. All eligible patients will be treated daily with cobimetinib in 28-day cycles. Cobimetinib will be administered for three weeks followed by a one week break prior to the start of the following cycle. Patients will remain on study therapy until treatment discontinuation criteria is met.

Timeline

Start

2021-01-12

Primary completion

2025-04-02

Completion

2026-08

Drugs

Indications